Daliya B.

Daliya B. has significant experience in the field of biomedical research and drug discovery. Daliya is currently the Associate Director of Cancer Biology at Ensem Therapeutics since December 2021. Prior to that, they worked at Nirogy Therapeutics as the Director of Biology for drug discovery from October 2020 to December 2021.

Daliya B. also has extensive experience at Novartis Institutes for BioMedical Research (NIBR). Daliya served as a Project Leader, Lab Head, and Principal Scientist II from September 2019 to October 2020, and as a Project Leader, Lab Head, and Principal Scientist I from September 2016 to August 2019.

Before joining Novartis, Daliya B. was a Project Lead and Scientist II at Biogen from July 2011 to November 2015. Daliya began their career in 2006 as a Postdoctoral Fellow at Harvard Medical School, specifically in the Immune Disease Institute at Boston's Children's Hospital. Daliya held this position until July 2011.

Overall, Daliya B. has gained expertise in various roles and has contributed significantly to the field of biomedical research and drug discovery throughout their career.

Daliya B. completed their education from 2000 to 2006 at Brandeis University, where they pursued a PhD in Cell and Molecular Biology with a specialization in Immunology.